Quality metrics fall below the minimum acceptable threshold — driven by the absence of any competitive moat and only moderate free cash flow margins — while a 17% short interest and an extreme put/call ratio of 13.29 amplify downside risk. A recent executive change adds organizational uncertainty, and a four-quarter earnings record that alternates between large beats and material misses offers no reliable operational anchor.
Thesis pillars
- Below Quality Floor→Stable
- Extreme Bearish Options Positioning↑Improving
- Inconsistent Earnings Execution→Stable
- +1 more pillar — see the Why tab for full reasoning
Bruker Corporation (BRKR) Stock Analysis
Breakout setup
Healthcare · Medical Devices
Sell if holding. Analyst target reached at $59.41 — A.R:R is negative (-1.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2).
Bruker designs and manufactures high-performance scientific instruments across four segments — BSI BioSpin (NMR, preclinical imaging), BSI CALID (mass spectrometry, diagnostics), BSI NANO, and BEST — serving life science, pharmaceutical, and industrial markets globally. About... Read more
Sell if holding. Analyst target reached at $59.41 — A.R:R is negative (-1.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2). Chart setup: Golden cross, above all MAs, RSI 55, MACD bullish. Score 5.1/10, moderate confidence.
Passes 5/7 gates (positive momentum, clean insider activity, earnings proximity 59d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-09-04Recent Developments — Bruker Corporation
Latest news
- NEWS Bruker, Luvata Team Up To Boost Superconductor Supply For Fusion Power Projects — benzinga Sep 4, 2026 positive
- NEWS Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit — benzinga Aug 31, 2026 neutral
- NEWS Bruker Announces Expanded Strategic Collaboration With And Minority Investment In Self-Driving Labs Firm Atinary Technol — benzinga Aug 11, 2026 positive
- NEWS Bruker Announces Majority Investment In Organ-On-A-Chip Developer MIMETAS, Expanding Into Microphysiological Systems For — benzinga Aug 10, 2026 positive
- NEWS Citigroup Maintains Neutral on Bruker, Lowers Price Target to $53 — benzinga Aug 5, 2026 neutral
Generated 2026-09-04T13:22:02Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMGeographicChina10-K Item 1A: 'A significant portion of our revenue is derived from sales into China... Our revenue in China for the year ended December 31, 2025, was $475.8 million'
- MEDIUMCustomerU.S. academic and government-funded customers10-K Item 1A: 'A meaningful portion of our revenue is derived from U.S. academic institutions, research organizations and other entities that rely in part on U.S. academic and government funding'
Material Events(8-K, last 90d)
- 2026-04-10Item 5.02MEDIUMFalko Busse, Ph.D., executive officer and President of Bruker BioSpin Group, agreed to transition duties on or around May 1, 2026, with employment ending Oct 31, 2026. Separation includes severance of approx. $1.02M (CHF equivalent). No successor named.SEC filing →
- 2026-04-01Item 5.02LOWThierry L. Bernard, CEO and Managing Director of QIAGEN N.V., appointed to Board of Directors effective April 1, 2026 as Class III director, filling a newly created vacancy as Board expanded from 11 to 12 directors. No reason cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $59.41 — A.R:R is negative (-1.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2). Chart setup: Golden cross, above all MAs, RSI 55, MACD bullish. Prior stop was $55.25. Score 5.1/10, moderate confidence.
Take-profit target: $60.60 (-14.0% upside). Prior stop was $55.25. Stop-loss: $55.25.
Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2); Weak growth.
Bruker Corporation trades at a P/E of N/A (forward 24.7). TrendMatrix value score: 5.3/10. Verdict: Sell.
21 analysts cover BRKR with a consensus score of 3.9/5. Average price target: $59.
What does Bruker Corporation do?Bruker designs and manufactures high-performance scientific instruments across four segments — BSI BioSpin (NMR,...
Bruker designs and manufactures high-performance scientific instruments across four segments — BSI BioSpin (NMR, preclinical imaging), BSI CALID (mass spectrometry, diagnostics), BSI NANO, and BEST — serving life science, pharmaceutical, and industrial markets globally. About 74% of fiscal 2025 revenue came from non-U.S. operations, with major customers including pharma companies, academic institutions, and hospitals. Corporate headquarters is in Billerica, Massachusetts, with manufacturing in Europe and North America.